DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ)

$10.61 0.01 (0.0943%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 73

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) News Sources

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company

16-08-2025

yahoo.com

DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) Sentiment Trend

0 25 50 75 100 73 16-08-2025 #1 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) FAQs

toggle

What is the current price of DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ)?

The current price of DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) is $10.61.


toggle

DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) absolute price change since previous trading day?

The absolute price change of DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) since the previous trading day is $0.01.


toggle

DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) percentage price change since previous trading day?

The percentage price change of DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) since the previous trading day is 0.0943%.


toggle

What is the most recent average sentiment score for DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ)?

The most recent average sentiment score for DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) is 73 out of 100.


toggle

What is the most recent average sentiment for DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ)?

The most recent sentiment for DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ) is .


SEC-8K** Filing Available For DRUGS MADE IN AMERICA ACQUIS (DMAA:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.